Received Oct 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Flulaval administration of an expired dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a specified number of patients who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (expiry date 30-JUN-2025) for prophylaxis. On 29-SEP-2025, the patients received FluLaval 2024-2025 season. On 29-SEP-2025, an unknown time after receiving FluLaval 2024-2025 season, the patients experienced expired vaccine used (Verbatim: Flulaval administration of an expired dose). The outcome of the expired vaccine used was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 29-SEP-2025 A pharmacist contacted the medical team on behalf of a physician to report that, on that day, seven patients had received expired doses of the Flulaval vaccine. The pharmacist inquired about potential side effects, whether any issues should be expected, and whether the vaccine should be re-administered to the affected patients. The healthcare provider did not provide the lot number of the Flulaval vaccine. Additionally, the pharmacist did not have specific patient details but mentioned that all recipients were likely above 60 years of age. The batch number was not provided upon follow- up with the reporter.